Page last updated: 2024-11-02

pioglitazone and MS (Multiple Sclerosis)

pioglitazone has been researched along with MS (Multiple Sclerosis) in 6 studies

Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.

Research Excerpts

ExcerptRelevanceReference
"Treatment with metformin and pioglitazone has beneficial anti-inflammatory effects in patients with MS and MetS and should be further explored."5.43Immunologic Effects of Metformin and Pioglitazone Treatment on Metabolic Syndrome and Multiple Sclerosis. ( Correale, J; Farez, MF; Negrotto, L, 2016)
"Treatment with metformin and pioglitazone has beneficial anti-inflammatory effects in patients with MS and MetS and should be further explored."1.43Immunologic Effects of Metformin and Pioglitazone Treatment on Metabolic Syndrome and Multiple Sclerosis. ( Correale, J; Farez, MF; Negrotto, L, 2016)

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (83.33)29.6817
2010's1 (16.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Negrotto, L1
Farez, MF1
Correale, J1
Feinstein, DL2
Galea, E1
Gavrilyuk, V1
Brosnan, CF1
Whitacre, CC1
Dumitrescu-Ozimek, L1
Landreth, GE1
Pershadsingh, HA1
Weinberg, G1
Heneka, MT3
Schmidt, S1
Moric, E1
Schmidt, M2
Sastre, M2
Klotz, L1
Giese, T1
Knolle, P1
Klockgether, T1
Peiris, M1
Monteith, GR1
Roberts-Thomson, SJ1
Cabot, PJ1
Niino, M1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Drug Repurposing Using Metformin for Improving the Therapeutic Outcome in Multiple Sclerosis Patients[NCT05298670]Phase 280 participants (Anticipated)Interventional2022-02-01Recruiting
Pilot Test of ACTOS in Multiple Sclerosis: Safety and Tolerability[NCT00242177]Phase 130 participants Interventional2003-10-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

1 review available for pioglitazone and MS (Multiple Sclerosis)

ArticleYear
Peroxisome proliferator-activated receptor agonists as potential therapeutic agents in multiple sclerosis.
    Mini reviews in medicinal chemistry, 2007, Volume: 7, Issue:11

    Topics: Animals; Anti-Inflammatory Agents; Encephalomyelitis, Autoimmune, Experimental; Humans; Multiple Scl

2007

Other Studies

5 other studies available for pioglitazone and MS (Multiple Sclerosis)

ArticleYear
Immunologic Effects of Metformin and Pioglitazone Treatment on Metabolic Syndrome and Multiple Sclerosis.
    JAMA neurology, 2016, 05-01, Volume: 73, Issue:5

    Topics: Adipokines; Anti-Inflammatory Agents; Brain; Cohort Studies; Cytokines; Disability Evaluation; Dose-

2016
Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis.
    Annals of neurology, 2002, Volume: 51, Issue:6

    Topics: Animals; Cerebellum; Cerebral Cortex; DNA-Binding Proteins; Encephalomyelitis, Autoimmune, Experimen

2002
Anti-inflammatory and antiproliferative actions of PPAR-gamma agonists on T lymphocytes derived from MS patients.
    Journal of leukocyte biology, 2004, Volume: 75, Issue:3

    Topics: Adjuvants, Immunologic; Adolescent; Adult; Anti-Inflammatory Agents; Case-Control Studies; Cell Divi

2004
Proinflammatory stimulation and pioglitazone treatment regulate peroxisome proliferator-activated receptor gamma levels in peripheral blood mononuclear cells from healthy controls and multiple sclerosis patients.
    Journal of immunology (Baltimore, Md. : 1950), 2005, Oct-15, Volume: 175, Issue:8

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cells, Cultured; Diabetes Mellitus, Type 2; DNA; Fem

2005
A model of experimental autoimmune encephalomyelitis (EAE) in C57BL/6 mice for the characterisation of intervention therapies.
    Journal of neuroscience methods, 2007, Jul-30, Volume: 163, Issue:2

    Topics: Adjuvants, Immunologic; Animals; Central Nervous System; Chemotaxis, Leukocyte; Disability Evaluatio

2007